Phase I Study of Paclitaxel, Carboplatin, and Increasing Days of Prolonged Oral Etoposide in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

1996 • 2,766 citations

Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results

2000 • 986 citations

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

1994 • 639 citations

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

1989 • 467 citations

Sequences of taxol and cisplatin: a phase I and pharmacologic study.

1991 • 438 citations

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

1998 • 393 citations

Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours

1991 • 373 citations

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.

1992 • 369 citations

Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian Cancer

1999 • 343 citations

Secondary Leukemia or Myelodysplastic Syndrome After Treatment With Epipodophyllotoxins

1999 • 287 citations

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.

1996 • 213 citations

Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.

1998 • 207 citations

Oral etoposide is active against platinum-resistant epithelial ovarian cancer.

1994 • 166 citations

Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study.

1997 • 138 citations

Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.

1997 • 138 citations

Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?

1998 • 85 citations

Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors.

1998 • 83 citations

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease

1994 • 72 citations

Secondary acute myelogenous leukemia following safe exposure to etoposide.

1997 • 69 citations

Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.

1997 • 66 citations

Prolonged Oral Etoposide in Recurrent or Advanced Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study

1998 • 65 citations

Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer

1992 • 54 citations

The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer.

1992 • 51 citations

Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines

1998 • 30 citations

Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer.

1998 • 29 citations

Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma

1996 • 27 citations

Phase I Study of Paclitaxel and Etoposide for Metastatic or Recurrent Malignancies

1998 • 7 citations

Combinations of paclitaxel and etoposide in the treatment of lung cancer.

1996 • 7 citations

A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)

1998 • 5 citations